AstraZeneca (LON:AZN) Stock Price Expected to Rise, Citigroup Analyst Says

AstraZeneca (LON:AZN) had its price objective boosted by analysts at Citigroup from £170 to £180 in a note issued to investors on Friday, Marketbeat reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price objective would suggest a potential upside of 17.89% from the stock’s current price.

Several other brokerages have also issued reports on AZN. Berenberg Bank lifted their price target on shares of AstraZeneca from £145 to £160 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Shore Capital Group reaffirmed a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of AstraZeneca from £105 to £110 and gave the stock a “sell” rating in a report on Thursday, January 15th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Thursday, January 15th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of £152.50.

AstraZeneca Stock Performance

LON:AZN opened at £152.69 on Friday. AstraZeneca has a 12-month low of GBX 9,651 and a 12-month high of £157.32. The company has a quick ratio of 0.59, a current ratio of 0.94 and a debt-to-equity ratio of 60.87. The firm has a 50-day moving average price of £146.93 and a 200 day moving average price of £137.50. The firm has a market capitalization of £236.79 billion, a PE ratio of 23.35, a price-to-earnings-growth ratio of 0.86 and a beta of 0.28.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.